Stem Cells Market to Reach USD 32.8 Billion by 2032 CAGR 9.9 percent DataHorizzon Research - Yahoo Finance
| PSTI Stock | ILS 1,944 66.00 3.28% |
About 61% of Pluristem's investor base is looking to short. The analysis of current outlook of investing in Pluristem suggests that many traders are alarmed regarding Pluristem's prospects. The current market sentiment, together with Pluristem's historical and current headlines, can help investors time the market. In addition, many technical investors use Pluristem stock news signals to limit their universe of possible portfolio assets.
Pluristem |
Stem Cells Market to Reach USD 32.8 Billion by 2032 CAGR 9.9 percent DataHorizzon Research Yahoo Finance
Read at news.google.com
 |
Pluristem Fundamental Analysis
We analyze Pluristem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pluristem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pluristem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Pluristem is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Pluristem Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pluristem stock to make a market-neutral strategy. Peer analysis of Pluristem could also be used in its relative valuation, which is a method of valuing Pluristem by comparing valuation metrics with similar companies.
Peers
Pluristem Related Equities
| ICB | Israel China | 9.41 | ||||
| MRIN | YD More | 8.61 | ||||
| AZRM | Azorim Investment | 3.41 | ||||
| AMOT | Amot Investments | 1.75 | ||||
| PRTC | Priortech | 0.12 | ||||
| ORA | Ormat Technologies | 0.10 | ||||
| CBI | Clal Biotechnology | 2.99 |
Complementary Tools for Pluristem Stock analysis
When running Pluristem's price analysis, check to measure Pluristem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pluristem is operating at the current time. Most of Pluristem's value examination focuses on studying past and present price action to predict the probability of Pluristem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pluristem's price. Additionally, you may evaluate how the addition of Pluristem to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |